Analysis of clinical outcomes in early breast cancer associated with PIK3CA mutations

Background. PIK3CA mutations are detected in up to 40 % of luminal breast cancer (BC) cases and are associated with hormone resistance. However, the prognostic significance of these mutations and their impact on the course of early BC remain debated. Aim. To analyze clinical and morphological factors determining prognosis of PIK3CA-associated early breast cancer. Materials and methods. A retrospective single-center cohort study was conducted. Among 635 patients who underwent molecular genetic testing, PIK3CA mutation was found in 230 (36.2 %). The final analysis included 133 patients with luminal HER2– early BC who received radical surgical treatment. Clinical and morphological characteristics, median recurrence-free survival (mRFS), and prognostic factors were assessed. Results. The common hotspot mutations H1047, E542, and E545 were detected in 88.7 % of patients and were associated with a better prognosis compared to rare mutations (mRFS 54 months vs 28 months; hazard ratio 0.57; log-rank p = 0.38). At initial diagnosis, tumor stage was I in 12.8 %, II in 50.4 %, and III in 36.8 % of cases. Overall mRFS in the entire radically treated cohort was 62 months (95 % confidence interval 48–76). Univariate analysis showed no statistically significant differences in mRFS for different immunohistochemical subtypes (luminal A vs luminal B; p = 0.62), administration of adjuvant radiotherapy (p = 0.39), or type of surgery (breast-conserving surgery vs mastectomy; p = 0.47). However, the use of neoadjuvant or adjuvant chemotherapy compared with no chemotherapy (62 months vs 31 months; hazard ratio 0.26; log-rank p = 0.01) and the choice of tamoxifen over aromatase inhibitors as adjuvant endocrine therapy (67 months vs 21 months; hazard ratio 0.17; log-rank p 0.0001) demonstrated significant effects. Conclusion. Early breast cancer with PIK3CA mutations is highly heterogeneous in clinical course and treatment sensitivity; development of hormone resistance is a distinct, clinically defined phenomenon (based on recurrence timing during endocrine therapy) and is not equivalent to mutation itself.

Authors

Institutions

Publication Details

Journal
MD-Onco
Published
2026-11-17
DOI
https://doi.org/10.17650/2782-3202-2026-6-3-34-44
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Analysis of clinical outcomes in early breast cancer associated with PIK3CA mutations

E G Topuzov, Рашида Вахидовна Орлова, Mark Igorevich Gluzman
MD-Onco
Breast Cancer Treatment Studies
article

Analysis of clinical outcomes in early breast cancer associated with PIK3CA mutations

E G Topuzov, Рашида Вахидовна Орлова, Mark Igorevich Gluzman
article en

Abstract

Background. PIK3CA mutations are detected in up to 40 % of luminal breast cancer (BC) cases and are associated with hormone resistance. However, the prognostic significance of these mutations and their impact on the course of early BC remain debated. Aim. To analyze clinical and morphological factors determining prognosis of PIK3CA-associated early breast cancer. Materials and methods. A retrospective single-center cohort study was conducted. Among 635 patients who underwent molecular genetic testing, PIK3CA mutation was found in 230 (36.2 %). The final analysis included 133 patients with luminal HER2– early BC who received radical surgical treatment. Clinical and morphological characteristics, median recurrence-free survival (mRFS), and prognostic factors were assessed. Results. The common hotspot mutations H1047, E542, and E545 were detected in 88.7 % of patients and were associated with a better prognosis compared to rare mutations (mRFS 54 months vs 28 months; hazard ratio 0.57; log-rank p = 0.38). At initial diagnosis, tumor stage was I in 12.8 %, II in 50.4 %, and III in 36.8 % of cases. Overall mRFS in the entire radically treated cohort was 62 months (95 % confidence interval 48–76). Univariate analysis showed no statistically significant differences in mRFS for different immunohistochemical subtypes (luminal A vs luminal B; p = 0.62), administration of adjuvant radiotherapy (p = 0.39), or type of surgery (breast-conserving surgery vs mastectomy; p = 0.47). However, the use of neoadjuvant or adjuvant chemotherapy compared with no chemotherapy (62 months vs 31 months; hazard ratio 0.26; log-rank p = 0.01) and the choice of tamoxifen over aromatase inhibitors as adjuvant endocrine therapy (67 months vs 21 months; hazard ratio 0.17; log-rank p 0.0001) demonstrated significant effects. Conclusion. Early breast cancer with PIK3CA mutations is highly heterogeneous in clinical course and treatment sensitivity; development of hormone resistance is a distinct, clinically defined phenomenon (based on recurrence timing during endocrine therapy) and is not equivalent to mutation itself.

MD-OncoVol. 6(3)
St Petersburg University (RU), City Clinical Oncology Center (RU), North-Western State Medical University named after I.I. Mechnikov (RU)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon